Lee's Pharmaceutical Holdings (FRA:L1PA) LT-Debt-to-Total-Asset: 0.03 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:L1PA Lee's Pharmaceutical Holdings Ltd FRA:L1PA
74 GF Score
Price €0.11
GF Value €0.17
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset?

Lee's Pharmaceutical Holdings FRA:L1PA +1.87% 74 LT-Debt-to-Total-Asset is 0.03 as of Dec. 2025. GuruFocus rates FRA:L1PA with a GF Score™ of 74/100 and a GF Value™ of €0.17. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lee's Pharmaceutical Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.03.

Lee's Pharmaceutical Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.03) to Dec. 2025 (0.03). It may suggest that Lee's Pharmaceutical Holdings is progressively becoming less dependent on debt to grow their business.

Lee's Pharmaceutical Holdings  (FRA:L1PA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Related Terms

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03
FRA:L1PA
74GF Score
Lee's Pharmaceutical Holdings Ltd FRA:L1PA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings LT-Debt-to-Total-Asset Calculation

Lee's Pharmaceutical Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=9.561/380.184
=0.03

Lee's Pharmaceutical Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=9.561/380.184
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.03 mean?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a LT-Debt-to-Total-Asset of 0.03 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lee's Pharmaceutical Holdings and its competitors.
Is Lee's Pharmaceutical Holdings' LT-Debt-to-Total-Asset too high?
Lee's Pharmaceutical Holdings' current LT-Debt-to-Total-Asset is 0.03. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Lee's Pharmaceutical Holdings' LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lee's Pharmaceutical Holdings and its competitors. Lee's Pharmaceutical Holdings's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (FRA:L1PA) has a current LT-Debt-to-Total-Asset of 0.03. The stock's GF Value™ is €0.17, compared to a current price of €0.11 — trading 35.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (FRA:L1PA), the current LT-Debt-to-Total-Asset is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lee's Pharmaceutical Holdings (FRA:L1PA) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of €0.11 is trading 35.9% below its estimated GF Value™ of €0.17.

Key valuation signals for FRA:L1PA:

  • LT-Debt-to-Total-Asset: 0.03
  • GF Value™: €0.17 vs. price of €0.11 (35.9% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for FRA:L1PA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.17
GF Value